Orphalan
| Type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 2011 |
| Headquarters | Paris, France |
| Key people | Naseem Amin (Chief Executive Officer) Shahzad Malik (Chairman of the Board) |
| Products | Trientine tetrahydrochloride/盐酸曲恩汀 (Cuprior/Cuvrior/科佩欧) |
Number of employees | 125 |
| Website | www.orphalan.com |
Orphalan S.A. is an orphan drug development and commercialization company headquartered in Paris, France. It specializes in the development of treatments for patients with Rare diseases.[1][2]
Its trientine tetrahydrochloride (盐酸曲恩汀) product, (branded as Cuprior in the EU[3] and some key markets, Cuvrior in the USA[4] and 科佩欧 (Ke Pei Ou) in China[5]) is a treatment for Wilson's disease, which is available in over 30 countries.[2]
History
Orphalan S.A. was founded in 2011.[2] In March 2016, trientine tetrahydrochloride (brand name Cuvrior in the USA) was granted orphan drug designation in the USA by the Food and Drug Administration (FDA) for the indication: treatment of Wilson's disease excluding patients intolerant to penicillamine.[6]
In September 2017, the European Medicines Agency (EMA) granted marketing authorization for trientine tetrahydrochloride (brand name Cuprior)[7] for the treatment of Wilson's disease in adults, adolescents and children ≥5 years intolerant to D-penicillamine therapy.[3]
In October 2017, Naseem Amin joined Orphalan as Chief Executive Officer.
In 2019, trientine tetrahydrochloride was launched commercially in the EU[8]
In 2021, the International Wilson Disease (iWD) Registry was established (a centralized database that is sponsored and managed by Orphalan SA).[9][1] This includes health data from consenting people with Wilson's disease from various countries around the world.[9][1]
In April 2022, trientine tetrahydrochloride (brand name Cuvrior in the USA) was approved by the FDA and granted Orphan Drug Exclusivity (ODE).[10] as a copper chelator indicated for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine, based on results from the CHELATE trial[10]
In September 2022, results from the CHELATE trial were published in The Lancet Gastroenterology & Hepatology.[11][12]
In November 2022, Shahzad Malik was appointed Chairman of the Orphalan Board.
In April 2023, trientine tetrahydrochloride was launched commercially in the USA.[8]
In December 2023, China's National Medical Products Administration (NMPA) approved trientine tetrahydrochloride (盐酸曲恩汀, brand name 科佩欧) for the treatment of Wilson's disease in adults, adolescents and children ≥5 years intolerant to D-penicillamine therapy.[5][13][14]
In March 2025, trientine tetrahydrochloride was launched commercially in China.[5]
Products
Trientine tetrahydrochloride, a copper-chelating agent for the treatment of Wilson's disease.[3][4]
References
- 1 2 3 "Our Work". Orphalan SA. Retrieved 2025-11-13.
- 1 2 3 "About Us". Orphalan SA. Retrieved 2025-11-13.
- 1 2 3 "Cuprior | European Medicines Agency (EMA)". www.ema.europa.eu. 2017-09-05. Retrieved 2025-11-13.
- 1 2 "DailyMed - CUVRIOR- trientine tetrahydrochloride tablet, film coated". dailymed.nlm.nih.gov. Retrieved 2025-11-27.
- 1 2 3 Kothari, Minesh (2025-03-07). "Orphalan becomes the first European company to enter in China's Wilson Disease market". Orphalan SA. Retrieved 2025-11-13.
- ↑ "Search Orphan Drug Designations and Approvals". www.accessdata.fda.gov. Archived from the original on 2025-04-16. Retrieved 2025-11-13.
- ↑ "Cuprior | European Medicines Agency (EMA)". www.ema.europa.eu. 2017-09-05. Retrieved 2025-11-27.
- 1 2 admin (2023-04-20). "Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease". Orphalan SA. Retrieved 2025-11-13.
- 1 2 "Home". Wilson's Disease Registry. Retrieved 2025-11-13.
- 1 2 admin (2022-05-02). "Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine". Orphalan SA. Retrieved 2025-11-27.
- ↑ Schilsky, Michael L.; Czlonkowska, Anna; Zuin, Massimo; Cassiman, David; Twardowschy, Carlos; Poujois, Aurelia; Gondim, Francisco de Assis A.; Denk, Gerald; Cury, Rubens G.; Ott, Peter; Moore, Joanna; Ala, Aftab; D'Inca, Renata; Couchonnal-Bedoya, Eduardo; D'Hollander, Koenraad (December 2022). "Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial". The Lancet. Gastroenterology & Hepatology. 7 (12): 1092–1102. doi:10.1016/S2468-1253(22)00270-9. ISSN 2468-1253. PMID 36183738.
- ↑ Kothari, Minesh (2022-09-30). "Orphalan announces publication of results from the CHELATE trial in The Lancet Gastroenterology & Hepatology". Orphalan SA. Retrieved 2025-11-27.
- ↑ admin (2024-01-18). "Orphalan announces China NMPA's approval of its trientine tetrahydrochloride product for the treatment of Wilson disease". Orphalan SA. Retrieved 2025-11-27.
- ↑ "国家药品监督管理局". www.nmpa.gov.cn. Archived from the original on 2025-06-12. Retrieved 2025-11-27.